Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidence-based Care's Genitourinary Cancer Disease Site Group

Table 3 Antimicrotubule trials: PSA and tumor response.

Trial	Treatment arms	PSA response*			Tumor response
		N	Response rate %	Statistical comparison	N	Objective response rate %	Statistical comparison
Tannock, 2004 [64]	docetaxel q 3 wks prednisone	291	45	p < 0.001	141	12	p = 0.1
	docetaxel q wk prednisone	291	48	p < 0.001	134	8	p = 0.6
	Mitoxantrone prednisone	300	32	NA	137	7	NA
Petrylak, 2004 [63]	Docetaxel EMP	309	50	p < 0.001	103	17	p < 0.30
	Mitoxantrone prednisone	303	27		93	11
Abratt, 2004 [62]	Vinorelbine hydrocortisone ± AGM	206	30.1	p < 0.01	68	5.9(PR)	NR
	hydrocortisone ± AGM	208	19.2		74	0
Berry, 2001 [84]	Paclitaxel EMP	166	48	p < 0.01	NR
	Paclitaxel		25
Hudes, 1999 [61]	vinblastine EMP	87	25.2	p < 0.0001	30	20 (PR)	p = 0.13
	Vinblastine	94	3.2		33	6 (PR)
Iversen, 1997 [65]	EMP	43	37.2	p = 0.001	NR
	Placebo	51	2.0
Johansson, 1991 [66]	EMP	NR			NR
	MPA
De Kernion, 1988 [67]	EMP	NR			102	0	p = NS
	Flutamide				101	1.0 (PR)
Murphy, 1979 [68]	EMP prednimustine	NR			54	1.9 (PR)	p = NS
	prednimustine				62	0

*PSA response was defined as = 50 decrease in PSA compared with baseline.
Abbreviations: AGM – aminoglutethimide; EMP – estramustine phosphate; MPA – medroxyprogesterone acetate; N – number; NA – not applicable; NR – not reported; NS – non-significant; PR – partial response; PSA – prostate-specific-antigen; q – every; wk(s) – week(s).

ISSN: 1471-2407